Breaking

Tweet TWEET

CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET

  CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow,
  April 4th at 8:00 A.M. ET

 To Provide An Update On Important Progress Being Made In R&D and Commercial
                                 Initiatives

CORRECTION...by ARIAD Pharmaceuticals, Inc.

Business Wire

CAMBRIDGE, Mass. -- April 3, 2013

First graph, last sentence of release should read: The Company will take
questions on the call. (sted The Company will not take questions on the call.)

The corrected release reads:

 ARIAD TO HOST INVESTOR CONFERENCE CALL TOMORROW, APRIL 4^TH AT 8:00 A.M. ET

 To Provide An Update On Important Progress Being Made In R&D and Commercial
                                 Initiatives

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will hold a
conference call for the investment community tomorrow, April 4, 2013 to
provide an update on its progress over the past several weeks with both its
commercial launch of Iclusig™ (ponatinib) in the United States and its
clinical development programs for Iclusig and AP26113. Harvey J. Berger, M.D.,
chairman and chief executive officer of ARIAD, will make a statement on these
and related topics. The Company will take questions on the call.

Tomorrow’s Conference Call at 8:00 a.m. ET

We will hold a live webcast and conference call tomorrow morning at 8:00 a.m.
ET. The live webcast can be accessed by visiting the investor relations
section of the Company’s website at http://investor.ariad.com. The call can be
accessed by dialing 800-884-5695 (domestic) or 617-786-2960 (international)
five minutes prior to the start time and providing the pass code 19013304. A
replay of the call will be available on the ARIAD website approximately two
hours after completion of the call and will be archived for three weeks.

About ARIAD

ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and
Lausanne, Switzerland, is an integrated global oncology company focused on
transforming the lives of cancer patients with breakthrough medicines. ARIAD
is working on new medicines to advance the treatment of various forms of
chronic and acute leukemia, lung cancer and other difficult-to-treat cancers.
ARIAD utilizes computational and structural approaches to design
small-molecule drugs that overcome resistance to existing cancer medicines.
For additional information, visit http://www.ariad.comor follow ARIAD on
Twitter (@ARIADPharm).

Contact:

ARIAD Pharmaceuticals, Inc.
For Investors
Kendra Adams, 617-503-7028
Kendra.adams@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
 
Press spacebar to pause and continue. Press esc to stop.